Marketing-authorisation holder · Canada
Natco Pharma (Canada) Inc
114 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
114 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 114
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| NAT-ABIRATERONE250 mg · Tablet | Abiraterone | Canada | Marketed | 2021 |
| NAT-ANASTROZOLE1 mg · Tablet | Anastrozole | Canada | Marketed | 2015 |
| NAT-APIXABAN2.5 mg · Tablet | Apixaban | Canada | Marketed | 2022 |
| NAT-APIXABAN5 mg · Tablet | Apixaban | Canada | Marketed | 2022 |
| NAT-BENDAMUSTINE25 mg / vial · Powder For Solution | Bendamustine | Canada | Marketed | 2021 |
| NAT-BENDAMUSTINE100 mg / vial · Powder For Solution | Bendamustine | Canada | Marketed | 2021 |
| NAT-BOSENTAN62.5 mg · Tablet | Bosentan | Canada | Not marketed | 2020 |
| NAT-BOSENTAN125 mg · Tablet | Bosentan | Canada | Not marketed | 2020 |
| NAT-CETIRIZINE10 mg · Tablet | Cetirizine | Canada | Marketed | 2020 |
| NAT-CETIRIZINE20 mg · Tablet | Cetirizine | Canada | Marketed | 2020 |
| NAT-ERIBULIN0.5 mg / ml · Solution | Eribulin | Canada | Not marketed | 2024 |
| NAT-ERLOTINIB25 mg · Tablet | Erlotinib | Canada | Not marketed | 2019 |
| NAT-ERLOTINIB100 mg · Tablet | Erlotinib | Canada | Not marketed | 2019 |
| NAT-ERLOTINIB150 mg · Tablet | Erlotinib | Canada | Not marketed | 2019 |
| NAT-EVEROLIMUS7.5 mg · Tablet | Everolimus | Canada | Authorised | |
| NAT-EVEROLIMUS10 mg · Tablet | Everolimus | Canada | Marketed | 2023 |
| NAT-EVEROLIMUS5 mg · Tablet | Everolimus | Canada | Marketed | 2023 |
| NAT-EVEROLIMUS2.5 mg · Tablet | Everolimus | Canada | Marketed | 2023 |
| NAT-GEFITINIB250 mg · Tablet | Gefitinib | Canada | Not marketed | 2019 |
| NAT-GRANISETRON1 mg · Tablet | Granisetron | Canada | Marketed | 2016 |
| NAT-IMATINIB400 mg · Tablet | Imatinib | Canada | Marketed | 2014 |
| NAT-IMATINIB100 mg · Tablet | Imatinib | Canada | Marketed | 2014 |
| NAT-LANTHANUM1000 mg · Tablet (Chewable) | Lanthanum carbonate | Canada | Marketed | 2020 |
| NAT-LANTHANUM250 mg · Tablet (Chewable) | Lanthanum carbonate | Canada | Marketed | 2020 |
| NAT-LANTHANUM500 mg · Tablet (Chewable) | Lanthanum carbonate | Canada | Marketed | 2020 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 114 | 77 | 37 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.